No Detail Found!

Comparison of the clinical efficacy of linagliptin with SGLT2 inhibitors in diabetic patients: A comparative cross-sectional study from Pakistan

Author(s)
Naureen Rehman Aga Khan University,Karachi,Pakistan
Muzna Hashmi Aga Khan University,Karachi,Pakistan
Sher Muhammad Sethi Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Sara Hafeez Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Aimun Shabbir Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Muhammad Ali Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Varisha Madni Aga Khan University,Karachi,Pakistan
Muhammad Zain Mushtaq Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Saad Bin Zafar Mehmood Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Faheem Shaikh Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Farhala Baloch Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Rabeea Azmat Department of Medicine, Aga Khan University Hospital,Karachi, Pakistan
Sumera Batool Department of Medicine, Aga Khan University Hospital,Karachi,Pakistan
Ainan Arshad Department of Medicine, Aga Khan University Hospital,Karachi,Pakistan
Abstract
This study compares linagliptin and SGLT-2 inhibitors to optimize diabetes management by evaluating their glycemic and non-glycemic effects. A cross-sectional study was conducted at the Aga Khan University Hospital, Karachi, from May to October 2023. Patients using linagliptin were assigned to group 1, while those on SGLT-2 inhibitors comprised group 2. Frequencies and percentages were used for categorical variables, and mean with standard deviation (SD) for continuous variables. An independent t-test assessed clinical outcomes before and after six months of treatment, with a significance threshold of p<0.05. Of the 278 patients enrolled (mean age: 53 years, SD: 13.4; 55.2% male), 39 were in group 1, and 239 in group 2. SGLT-2 inhibitors showed a greater reduction in HbA1c (-0.66 vs. -0.46, p=0.002) and diastolic blood pressure (mean difference: 2.65 mmHg, p=0.005). Linagliptin significantly reduced BMI (mean difference: 0.65 kg/m², p=0.03), while no significant weight change was observed with SGLT-2 inhibitors. SGLT-2 inhibitors provided superior glycemic control and reduced blood pressure, while linagliptin was more effective in lowering BMI. Further studies are needed to explore linagliptin's potential benefits.
Publication Details
Page(s) 1509-1514
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 4, Year: 2025

Request the full text from PASTIC

Keywords
Diabetes, Diabetes, Diabetes, Glycemic control, HbA1C, Linagliptin, SGLT-2 inhibitors
References
Aljohani H,Alrubaish FS,Alghamdi WM,Al-Harbi F .2024 .Safety of linagliptin in patients with type 2 diabetes mellitus: A systematic review and metaanalysis of randomized clinical trials. Ther Innov Regul Sci, 58(4) : 622-633.
Bhutta ZA,Ul Haq Z and Basit A .2022 .Diabetes in Pakistan: Addressing the crisis. Lancet Diabetes Endocrinol, 10(5) : 309-310.
Caleyachetty R,Barber TM,Mohammed NI,Cappuccio FP,Hardy R,Mathur R,Banerjee A,Gill P,Daza-Arnedo R,Rico-Fontalvo JE,Pájaro-Galvis N,LealMartínez V,Abuabara-Franco E,Raad-Sarabia M,Montejo-Hernández J,Cardona-Blanco M,CabralesJuan J,Uparella-Gulfo I,Montiel LS .2021 .Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: A narrative review. Kidney Med, 3(6) : 1065-1073.
Hashimoto-Kameda R,Cho KY,Nomoto H,Nakamura A,Omori K,Nagai S,Edagawa S,Kawata S,Takeuchi J,Kameda H,Kurihara Y,Aoki S,Atsumi T,Miyoshi H T .2021 .Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). Diabetes Res Clin Pract, 180 : 109069.
Laffel LM,Danne T,Klingensmith GJ,Tamborlane WV,Willi S,Zeitler P,Neubacher D,Marquard J .2023 .Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): A multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. , 11(3) : 169-81.
Lazzaroni E,Ben Nasr M,Loretelli C,Pastore I,Plebani L,Lunati ME,Vallone L,Bolla AM,Rossi A,Montefusco L,Ippolito E,Berra C,D'Addio F,Zuccotti GV,Fiorina P .2021 .Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res, 171 : 105782.
Lee SJ,Lee KH,Oh HG,Seo HJ,Jeong SJ,Kim CH .2019 .Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitus and coronary artery disease. J Obes Metab Syndr., 28(4) : 254-61.
Lin WR,Liu KH,Ling TC,Wang MC,Lin WH .2023 .Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease. World J Diabetes, 14(4) : 352-63.
Mingrone G,Castagneto-Gissey L,Bornstein SR .2022 .New horizons: Emerging antidiabetic medications. J Clin Endocrinol Metab, 107(12) : e4333-e40.
Nagayama A,Inokuchi T,Ashida K,Inada C,Homma T,Miyazaki H,Adachi T,Iwata S,Motomura S,Nomura M .2024 .Kurume medical study group of internal medicine. assessing the metabolic and physical effects of combined dpp4 and sglt2 inhibitor therapy in patients with type-2 diabetes mellitus: An observational prospective pilot study. JMA J, 7(3) : 387-400.
Saisho Y .2020 .Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. Diabetes Metab, 46(3) : 186-196.
Son C,Makino H,Kasahara M,Tanaka T,Nishimura K,Taneda S,Nishimura T,Kasama S,Ogawa Y,Miyamoto Y,Hosoda K Y .2021 .Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study. Diabetes Res Clin Pract, 180 : 109037.
Suzuki Y,Kaneko H,Okada A,Ohno R,Yokota I,Fujiu K,Jo T,Takeda N,Morita H,Node K,Yasunaga H,Komuro I .2024 .Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus. J Endocrinol Invest, 47(5) : 1261-70.
0

Citations

0

Downloads

95

Views